References
- De Rooij M, Hamon EH, Futterer JJ, Barentsz JO and Rovers MM: Accuracy
of multiparametric MRI for prostate cancer detection: a meta analysis.
AJR Am J Roentgenol 202: 343-351, 2014.
- Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of
MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for
the diagnosis of prostate cancer. JAMA 313: 390-397, 2015
- Cohen MS, Hanley RS, Kurteva T, et al. Comparing the Gleason prostate
biopsy and Gleason prostatectomy grading system: the Lahey Clinic
Medical Center experience and an international meta-analysis. Eur
Urol. 2008;54:371-81.
- Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading
of prostate cancer from biopsy to radical prostatectomy: incidence and
predictive factors using the modified Gleason grading system and
factoring in tertiary grades. Eur Urol 2012; 61: 1019-24.
- Alchin DR, Murphy D, Lawrentschuk N. Risk factors for Gleason score
upgrading following radical prostatectomy. Minerva Urol Nefrol 2017
;69: 459-465.
- Diamand R, Oderda M, Al Hajj Obeid W, et al. A multicentric study on
accurate grading of prostate cancer with systematic and MRI/US fusion
targeted biopsies: comparison with final histopathology after radical
prostatectomy. World J Urol. 2019 Oct;37(10):2109-2117. doi:
10.1007/s00345-019-02634-9. Epub 2019 Jan 16.
- Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and
Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020 Mar
5;382(10):917-928.
- Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of
multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a
paired validating confirmatory study. Lancet. (2017) 389:815–22. doi:
10.1016/S0140-6736(16)32401-1
- Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or
standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;
378:1767–77.
- Rührup J, Preisser F, Theißen L, et al. MRI-Fusion Targeted vs.
Systematic Prostate Biopsy-How Does the Biopsy Technique Affect
Gleason Grade Concordance and Upgrading After Radical Prostatectomy?
Front Surg. 2019 Sep 18;6:55. doi: 10.3389/fsurg.2019.00055.
eCollection 2019.
- Goel S, Shoag JE, Gross MD, et al. Concordance Between Biopsy and
Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A
Systematic Review and Meta-analysis. Eur Urol Oncol. 2020
Feb;3(1):10-20. doi: 10.1016/j.euo.2019.08.001. Epub 2019 Sep 4.
- Porpiglia F, DE Luca S, Passera R, et al. Multiparametric Magnetic
Resonance/Ultrasound Fusion Targeted Biopsy Improves Agreement Between
Biopsy and Radical Prostatectomy Gleason Score. Anticancer Res. 2016;
36: 4883-9.
- Borkowetz
A, Platzek I, Toma M, et al. Direct comparison of multiparametric
magnetic resonance imaging (MRI) results with final histopathology in
patients with proven prostate cancer in
MRI/ultrasonography-fusion biopsy.
BJU
Int. 2016 Aug;118(2):213-20.
- D. Lea J, Stephensond S, Bruggerd M, et al. MRI-ultrasound fusion
biopsy for prediction of final prostate pathology. J Urol. 2014
November ; 192(5): 1367–1373.
- Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging
— Reporting and Data System: 2015, version 2. Eur Urol 2016; 69:
16-40.
- Epstein JI, Egevad L, Amin MB, et al.The 2014 International Society of
Urological Pathology (ISUP) Consensus Conference on Gleason Grading of
Prostatic Carcinoma: definition of grading patterns and proposal for a
new grading system. Am J Surg Pathol. 2016; 40(2):244–52.
- Harris PA,Taylor R,Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap) – A metadata-driven
methodology and workflow process for providing translational research
informatics support. J Biomed Inform. 2009;42(2):377-81.
- Harris PA,Taylor R, Minor BL, et al. REDCap Consortium, The
REDCap consortium: Building an international community of software
partners. J Biomed Inform. 2019 May 9 [doi:
10.1016/j.jbi.2019.103208]
- Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value
of the Gleason score in prostate cancer. BJU Int 2002; 89: 538-542.
- van
Luijtelaar A, Bomers J, Fütterer J. A comparison of magnetic
resonance imaging techniques used to secure biopsies in prostate
cancer patients.
Expert
Rev Anticancer Ther. 2019 Aug;19(8):705-716.
- Drost FH, Osses DF, Nieboer D, et al. Prostate MRI, with or without
MRI-targeted biopsy, and systematic biopsy for detecting prostate
cancer. Cochrane Database Syst Rev. 2019;4:CD012663.
- Alshak MN, Patel N, Gross MD, Margolis D, Hu JC. Persistent
Discordance in Grade, Stage and NCCN Risk Stratification in Men
Undergoing targeted Biopsy and Radical Prostatectomy. Urology 2020;
135: 117-123.
- Boesen
L. Multiparametric MRI in detection and staging of prostate cancer.
Dan Med J. 2017
Feb;64(2). pii: B5327.
- Drost FJH, Rannikko A, Valdagni R, et al. Can active
surveillance really reduce the harms of overdiagnosing prostate
cancer? A reflection of real life clinical practice in the PRIAS
study. Transl Androl Urol 2018; 7 : 98-105.
- Radtke JP, Kuru TH, Bonekamp D, et al. Further reduction of
disqualification rates by additional MRI-targeted biopsy with
transperineal saturation biopsy compared with standard 12-core
systematic biopsies for the selection of prostate cancer patients for
active surveillance. Prostate Cancer Prostatic Dis, 2016; 19: 283-291.
- Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA,
Guillonneau BD. Pathological upgrading and up staging with immediate
repeat biopsy in patients eligible for active surveillance. J Urol.
2008;180:1964-1967.
- Musunuru HB, Yamamoto T, Klotz L, et al. Active surveillance for
intermediate risk prostate cancer: survival outcomes in the sunnybrook
experience. J Urol. 2016;196:1651-1658.
- Patel HD, Tosoian JJ, Carter HB, Epstein JI. Adverse pathologic
findings for men electing immediate radical prostatectomy: defining a
favorable intermediate-risk group. JAMA Oncol. 2018;4:89-92.
- Tinay I, Aslan G, Kural AR, et al.
Pathologic
Outcomes of Candidates for Active Surveillance Undergoing Radical
Prostatectomy: Results from a Contemporary Turkish Patient Cohort.
Urol Int. 2018;100:43-49.
- Gondo T, Poonc BY ,Matsumotoa K, Bernsteina M, Sjobergc DD , Easthama
JA. Clinical role of pathological downgrading after radical
prostatectomy in patients with biopsy-proven Gleason score 3+4
prostate cancer. BJU Int. 2015 January ; 115: 81–86.